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Introduction
Venous thrombosis was ﬁrst linked to air travel in 1954,1
but remains topical. The results from studies suggest a
2–4-fold increased risk of thrombosis after air travel;2–4
with a greater risk after longer ﬂights than after shorter
ones.5,6 The mechanism of thrombus formation during
air travel, however, is unclear. Immobilisation for long
periods could play a part,7,8 as could ﬂight speciﬁc
factors—eg, hypobaric hypoxia, which might activate the
clotting system. Bendz and colleagues9 exposed
volunteers to a hypoxic and hypobaric environment
similar to that in an airplane. Markers of activated
coagulation—ie, prothrombin fragment 1 and 2 (F12)
and thrombin-antithrombin complex (TAT)—were
transiently increased, but these ﬁndings could have been
the result of artiﬁcial activation.10 In another similar
study,11 no differences were noted compared with a
control situation. Some studies done during air travel
have shown an increase in activity of clotting factor VII
and clotting factor VIII12 and of D-dimer con-
centrations,13 though one of young healthy men14
indicated no effects. Furthermore, few studies have
taken into account circadian variation and its possible
effect on clotting factors, or distinguished between
effects of immobilisation and hypoxic hypobaria. Finally,
studies have mostly included participants without risk
factors for thrombosis, whereas the risk of travel-related
thrombosis is mainly increased in the presence of the
factor V Leiden mutation and hormone use.3
Our aim, therefore, was to ascertain whether exposure to
an 8-h ﬂight leads to a hypercoagulable state, with
immobilisation and circadian rhythm accounted for.
Methods 
Participants
Between May 24 and July 10, 2004, we did a crossover
study in healthy volunteers, some of whom had risk
factors for thrombosis. Volunteers with the factor
V Leiden mutation were recruited by contacting partici-
pants of a previous study15 for which 60 asymptomatic
carriers had been identiﬁed after screening of 1083
students and employees aged 18–40 years at the
University of Utrecht, Netherlands. We also screened
healthy laboratory personnel of a participating clinic. We
recruited volunteers without the factor V Leiden mutation
by advertisement. Exclusion criteria were previous venous
thrombosis, recent (12 weeks) surgery or immobilisation
(including travel lasting 4 h or any air travel), active
cancer, any drug use except of oral contraceptives, preg-
nancy or puerperium, and diseases affecting coagulation. 
The medical ethics committee of the Academic Medical
Center, Amsterdam, approved the study, and all
participants gave written informed consent.
Procedures
We exposed all participants to an 8-h ﬂight, 8 h of
immobilisation (movie marathon), and 8 h of regular daily
activities, separating each exposure situation by 2 weeks or
more (based on the half lives of the clotting factors). This
design enabled us to investigate air travel with hypobaric
Lancet 2006; 367: 832–38
See Comment page 792
*This study was done in the
framework of the WRIGHT
initiative (WHO Research Into
Global Hazards of Travel).
Investigators listed at end of
article
Department of Vascular
Medicine, Academic Medical
Center, Amsterdam,
Netherlands (A J M Schreijer MD,
J C M Meijers PhD, 
S Middeldorp MD,
Prof H R Büller MD); and
Department of Clinical
Epidemiology 
(A J M Schreijer, 
S C Cannegieter MD, 
Prof F R Rosendaal MD) and
Department of Haematology
(Prof F R Rosendaal), Leiden
University Medical Center,
2300 RC Leiden, Netherlands
Correspondence to: 
Prof F R Rosendaal
f.r.rosendaal@lumc.nl
Activation of coagulation system during air travel: a crossover
study
A J M Schreijer, S C Cannegieter, J C M Meijers, S Middeldorp, H R Büller, F R Rosendaal*
Summary
Background There is an increased risk of venous thrombosis after air travel, but the underlying mechanism is unclear.
Our aim was to ascertain whether ﬂying leads to a hypercoagulable state. 
Methods We did a crossover study in 71 healthy volunteers (15 men, 56 women), in whom we measured markers of
activation of coagulation and ﬁbrinolysis before, during, and after an 8-h ﬂight. The same individuals participated in two
control exposure situations (8-h movie marathon and daily life) to separate the effect of air travel on the coagulation
system from those of immobilisation and circadian rhythm. To study the effect of risk factors for thrombosis, we
included participants with the factor V Leiden mutation (n=11), those who took oral contraceptives (n=15), or both
(n=15), as well as 30 individuals with no speciﬁc risk factors.
Findings After the ﬂight, median concentrations of thrombin-antithrombin (TAT) complex increased by 30·1% (95% CI
11·2–63·2), but decreased by 2·1% (11·2 to 14) after the cinema and by 7·9% (16·2 to 1·2) after the daily life
situation. We recorded a high response in TAT levels in 17% (11 of 66) of individuals after air travel (3% [2 of 68] for
movie marathon; 1% [1 of 70] in daily life). These ﬁndings were most evident in the group with the factor V Leiden
mutation who used oral contraceptives. We noted a high response in all variables (prothrombin fragment 1 and 2, TAT,
and D-dimer) in four of 63 (6·3%) volunteers after the ﬂight, but in no-one after either of the control situations.
Interpretation Activation of coagulation occurs in some individuals after an 8-h ﬂight, indicating an additional
mechanism to immobilisation underlying air travel related thrombosis.
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hypoxia controlled for effects of immobilisation at ground
level and for circadian rhythm. We drew blood before,
during, and after each exposure, at the same time of day. 
For the ﬁrst exposure situation, we chartered a Boeing
757 for a non-stop day ﬂight of 8 h from and to Schiphol
airport, Amsterdam. We instructed volunteers not to
smoke, use drugs, drink alcohol, or take any prophylactic
measures to prevent thrombosis—eg, heparin or aspirin
use, or wearing of elastic stockings during the ﬂight—to
remain seated as much as possible, and to keep a
structured record of ﬂuid intake. 2–3 weeks after the ﬂight,
all participants sat for 8 h (for practical reasons two
sessions with half the participants in each) in a cinema.
We imposed the same restrictions during this second
exposure situation as in the ﬁrst with respect to moving,
drugs, smoking, and drinking, and again asked partici-
pants to keep a record of their ﬂuid intake. For the ﬁnal
exposure situation, 2 weeks after the movie marathon, we
asked participants to live their lives as they normally
would for a day, recording ﬂuid intake. We asked partici-
pants not to drink alcohol, take drugs, or smoke, but did
not restrict movement. We asked participants to keep their
food and ﬂuid intake constant during the three exposures.
Experienced technicians did the blood sampling (each
time by fresh venepuncture) and recorded when blood
was obtained and any problems that arose during
sampling. Baseline blood sampling took place after an
overnight fast before each exposure situation. Blood
sampling took place between 0800 and 0830 h, around
noon, and between 1630 h and 1730 h on the day of each
exposure. 
We centrifuged citrated (3·2%) blood twice within
15 min of venepuncture at 2500 g for 15 minutes at 15°C,
and froze and immediately stored the plasma at 80°C.
We extracted DNA from EDTA-anticoagulated blood and
stored it at 4°C. We did the assays (all in duplicate except
for the DNA tests) after all participants had completed the
study. We assayed the TAT complexes and F12 by
sandwich-type ELISA (Dade-Behring, Marburg,
Germany). We measured D-dimer concentrations with
the VIDAS D-dimer new (DD2) immunoassay and the
miniVIDAS analyser (BioMerieux, Marcy-l’Etoile, France).
We ascertained factor V Leiden and prothrombin
G20210A status by PCR. 
Statistical analyses
We report the general characteristics of the volunteers as
means and ranges. We calculated the median (95% CI) of
the concentrations of the markers of activation of the
coagulation and ﬁbrinolytic system overall and for
subgroups for each of the three exposures. We compared
the levels of each marker after exposure to the ﬂight, to the
movie marathon, and to the daily life situation with the
Friedman test. This test is a non-parametric equivalent of
a one-sample repeated measures design or a two-way
analysis of variance, with one observation per cell. We
calculated relative changes in the variables for each
individual by subtracting the pre-exposure value from the
post-exposure value, dividing it by the pre-exposure value,
and multiplying the result by 100%. We calculated the
medians (95% CI) of these individual changes. 
We identiﬁed high responders for each assay by using as
cutoff points the mean plus three times the SD for the
relative change in that assay during the daily life situation.
We also did this analysis with two times and four times
the SD, which changed the numbers but not the overall
pattern (data not reported). We compared the frequency of
high-responders in each of the three exposure groups with
Fisher’s exact test. For all individuals identiﬁed as high
responders, we checked whether there had been any
difﬁculties during blood sampling, whether vasovagal
collapse had occurred, and whether patterns of response
were related to seating location or the designated
technician.
Role of the funding source
The sponsor had no role in study design, data collection,
data analysis, data interpretation, or the writing of the
report. The corresponding author had full access to all the
data in the study and had ﬁnal responsibility for the
decision to submit for publication.
Results 
The ﬂight took place on May 24, 2004, between 0830 h and
1619 h (ﬂight time 7 h 49 min). There were no delays and
no turbulence. The cabin pressure corresponded to an
altitude of 1800–2100 m, and the cruising altitude was
11 000–12 000 m. The movie marathon took place on June
5 and June 12, 2004, between 08·30 h and 1630/1700 h.
Movies shown were similar to those shown in-ﬂight—ie,
adventure and comedy. We drew blood for assessment of
the daily life exposure situation in the last week of June or
the ﬁrst week of July. Fluid intake was similar during the
3 exposure days. 
71 healthy volunteers aged 20–39 years participated in
the study, of whom 56 (79%) were women (table 1). Of the
60 asymptomatic female carriers of the factor V Leiden
mutation who were enrolled to the study by Kemmeren
and colleagues (all heterozygous),15 we traced 53. Of these,
25 were eligible, willing, and available to participate. We
also included one other carrier of the factor V Leiden
mutation, whom we identiﬁed through screening of
healthy employees at a participating clinic. 15 of these
26 women with the factor V Leiden mutation used oral
contraceptives. Of 60 people who responded to our
advertisement, 49 were eligible and 45 were included
(table 1). All volunteers returned for each stage in the
study as planned. There were no episodes of venous
thrombosis during the study.
We took 639 blood samples from the 71 volunteers
during nine timepoints. 14 samples (2%) were unavailable
for analysis: ten were visibly haemolytic, three were
missing because of unsuccessful blood collection, and in
one results were technically unreliable. Missing samples
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were evenly distributed across the three exposure groups.
For the measurement of D-dimer concentrations, three
further samples could not be used.
During analyses, we did not identify any additional
carriers of the factor V Leiden mutation, but we did
identify one individual with a heterozygous prothrombin
G20210A mutation. We left her in her group (no factor V
Leiden mutation and no oral contraceptive use) for
analysis; she did not respond differently from the other
volunteers in her group to any of the three situations. 
Median TAT baseline values were similar for the three
exposures (ﬁgure 1), but were higher after the ﬂight
(2·8 g/L, 95% CI 2·4–3·2) than after the movie
marathon (2·2 g/L, 1·9–2·5) or the daily life situation
(1·7 g/L, 1·6–2·0). The Friedman test showed a clear
difference between the three after-values (p0·0001),
indicating a strong effect on an individual level. The TAT
values of 33 of 71 individuals were highest after the ﬂight,
whereas in 15 they were highest after the movie marathon,
and in only ten were they highest after the daily life
situation. This individual effect was conﬁrmed when,
compared with baseline values, the median of the
individual relative changes in TAT increased by 30·1%
(11·2–63·2) after the ﬂight, but decreased by 2·1%
(11·2 to 14·0) after the cinema and by 7·9% (16·2 to
1·2) after the daily life situation. The median TAT
values after the ﬂight, compared with those after the
cinema and the daily life situation, were higher in most
subgroups, but most clearly so in the group of women
with the factor V Leiden mutation who also took oral
contraceptives (ﬁgure 2). The median values in this group
were 5·2 g/L (3·2–7·5) after the ﬂight, 2·6 g/L
(1·9–3·5) after the cinema, and 1·9 g/L (1·4–2·4) after
the daily life situation. With respect to TAT, 11 of
66 individuals (16·7%, 95% CI 8·6–27·9) were identiﬁed
as high responders after the ﬂight (table 2, table 3, ﬁgure
3). In the cinema exposure, two other individuals (2 of 68,
2·9%, 0·4–10·2) were identiﬁed as high responders. The
daily life situation led to one high-responder (1 of 70,
1·4%, 0·0–7·7). She was also a high-responder during the
ﬂight (table 2, table 3, and ﬁgure 3).
Median baseline values of F12 were higher before the
cinema exposure than before the other two exposure
situations (ﬁgure 1). After the ﬂight and the cinema
exposures, the median F12 levels were the same 
(0·59 nmol/L, 95% CI 0·56–0·63) and lower than after the
daily life exposure situation (0·62 nmol/L, 0·58–0·66,
Friedman test for difference between the three after
values: p=0·050, again with most individual levels highest
after the ﬂight). The median of the individual relative
changes in F12 was 9·9% (12·8 to 4·3) after the
ﬂight, 14·1% (20·7 to 12·0) after the cinema, and
8·2% (11·6 to 5·2) after the daily life situation.
Within each subgroup separately, we did not ﬁnd a clear
difference between the F12 levels after the three
exposure situations (ﬁgure 2). We identiﬁed six
All (n=71) Men (n=15) Women (n=56)
FVL/OC (n=15) FVL/OC (n=11) FVL/OC (n=15) FVL/OC (n=15)
Age (years) 28 (20–39) 28 (22–37) 28 (20–37) 32 (26–39) 24 (20–34) 28 (25–33)
Body-mass index (kg/m2) 23·0 (18–33) 24·9 (20·0–33·0) 21·6 (18·0–27·1) 22·8 (18·5–27·0) 22·5 (19·6–27·4) 23·2 (19·0–28·3)
Height (m) 1·75 (1·57–1·97) 1·84 (1·70–1·97) 1·73 (1·62–1·90) 1·73 (1·61–1·88) 1·73 (1·60–1·83) 1·72 (1·57–1·86)
Data are mean (range). FVL/=factor V Leiden mutation present/absent. OC/=oral contraceptive use or not.
Table 1: Characteristics of volunteers
M
ed
ia
n 
TA
T 
co
nc
en
tr
at
io
n 
(
g/
L)
3·0
2·5
2·0
1·5
1·0
0·5
0
M
ed
ia
n 
F1

2 
co
nc
en
tr
at
io
n 
(n
m
ol
/L
)
0·8
0·7
0·6
0·5
0·4
0·3
0·2
0·1
0
M
ed
ia
n 
D
-d
im
er
 c
on
ce
nt
ra
ti
on
 (
g/
L)
250
200
150
100
50
0
F12 D-dimerTAT
Af
te
r d
ail
y l
ife
Du
rin
g d
ail
y l
ife
Be
fo
re 
da
ily
 lif
e
Af
te
r c
ine
m
a
Du
rin
g c
ine
m
a
Be
fo
re 
cin
em
a
Af
te
r f
lig
ht
Du
rin
g f
lig
ht
Be
fo
re 
flig
ht
Af
te
r d
ail
y l
ife
Du
rin
g d
ail
y l
ife
Be
fo
re 
da
ily
 lif
e
Af
te
r c
ine
m
a
Du
rin
g c
ine
m
a
Be
fo
re 
cin
em
a
Af
te
r f
lig
ht
Du
rin
g f
lig
ht
Be
fo
re 
flig
ht
Af
te
r d
ail
y l
ife
Du
rin
g d
ail
y l
ife
Be
fo
re 
da
ily
 lif
e
Af
te
r c
ine
m
a
Du
rin
g c
ine
m
a
Be
fo
re 
cin
em
a
Af
te
r f
lig
ht
Du
rin
g f
lig
ht
Be
fo
re 
flig
ht
Figure 1: Absolute median values of coagulation variables before, during, and after exposure situations (n=71)
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individuals (6 of 66, 9·1%, 3·4–18·7) as high responders
for F12 during the ﬂight (table 2, ﬁgure 3), compared
with only one after the cinema (1 of 68, 1·5%, 0·0–7·9%)
and the daily life situation (1 of 70, 1·4%, 0·0–7·7). The
woman with a high response in the daily life situation was
also a high responder during the ﬂight experiment
(table 2, ﬁgure 3).
Finally, median D-dimer level after the ﬂight rose to 
216 g/L (95% CI 182–240), but fell to 180 g/L (155–211)
after the cinema and was unaltered by normal daily
activity (198 g/L, 176–231 (ﬁgure 1), Friedman test for
difference between the three after values: p=0·012, again
with most individual levels highest after the ﬂight). The
median of the individual relative changes in D-dimer
values, compared with the baseline values, was 3·3%
after the ﬂight (8·5 to 2·2), 5·8% after the cinema
(12·8 to 2·2), and 5·5% after the daily life situation
(9·5 to 1·9). Within the subgroups, D-dimer levels
Group TAT F12 D-dimer 
Before After Change Before After Change Before After Change
(g/L) (g/L) (%) (nmol/L) (nmol/L) (%) (g/L) (g/L) (%) 
High responders after ﬂight*
3126 Female no FVL or OC 2·2 68·0 2991 0·60 2·59 332 208 1571 656 
3158 Female no FVL or OC 1·6 37·5 2244 0·39 1·43 267 126 354 180 
3147 Female OC only 1·9 30·7 1516 0·79 1·47 86  343 1353 294 
3136 Female FVL and OC 3·0 38·4 1180 0·83 1·47 77 493 822 67 
3148 Female OC only 1·7 15·4 806 0·63 0·87 38  142 209 48†  
3108 Female FVL and OC 3·7 20·8 462 0·77 1·35 75  Missing 444 Unknown
3138 Female FVL and OC 2·2 10·7 386 0·75 0·87 16† 228 323 42†
3110 Female FVL and OC 1·6 6·4 300 0·78 0·84 8† 232 216 7†
3143 Female FVL and OC 1·9 6·9 263 0·68 0·78 15† 202 311 54 
3169 Male 2·2 7·7 250 0·64 0·72 12† 352 403 14†
3163 Female FVL and OC 1·1 3·5 218 0·57 0·58 2† 130 128 2†
High responders after cinema*
3153 Female FVL and OC 2·5 33·7 1248 0·86 1·44 67 694 538 23†
3157 Female OC only 2·7 9·7 259 0·87 0·90 3† 189 193 2†
3120 Female no FVL or OC 5·5 10·3 87† 0·78 0·87 12† 139 211 52
High responders after daily life situation*
3143 Female FVL and OC 2·2 10·5 377 0·75 0·99 32† 206 248 21† 
3158 Female no FVL or OC 3·1 8·9 187† 0·44 0·65 48 133 143 7†
3120 Female no FVL or OC 1·7 1·9 12† 0·77 0·71 8† 287 455 58
3125 Female OC only 1·4 2·0 43† 0·66 0·59 11† 98 162 65
FVL=factor V Leiden mutation. OC=oral contraceptive use. Data are absolute values before and after exposure and relative change. *Number in group after ﬂight: TAT=66, F12=66, 
D-dimer=63; after cinema: TAT=68, F12=68, D-dimer=68; after daily life situation: TAT=70, F12=70, D-dimer=70. †Not a high responder for this measurement. Cut off point for high
responders (mean plus three times SD in daily life situation): TAT 202·9%, F12 37·3%, D-dimer 51·7%. 
Table 2: Individual data of high responders
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Figure 2: Absolute median values of coagulation variables after exposure situations, by subgroup
FVL=factor V Leiden mutation. OC=oral contraceptive use.
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were generally higher after the ﬂight than after the cinema
and daily life situation. This difference in levels was again
most obvious in the group with the factor V Leiden
mutation who were also taking oral contraceptives
(ﬁgure 2). The median values in this group were 306 g/L
(202–457) after the ﬂight compared with 219 g/L
(151–495) after the cinema and 240 g/L (197–355) after
the daily life situation (ﬁgure 2). The ﬂight caused a high
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Figure 3: Relative change in coagulation variables after exposure situations, by individual and ordered by change in TAT after ﬂight
Order of bars (individuals) consistent across panels. 
High responders 0 risk factors 1 risk factor 2 risk factors
(total number [%, 95% CI]) (number, %) (number, %) (number, %)
TAT 
Flight 11/66 (17%, 8·6–27·9) 3/29 (10%) 2/23 (9%) 6/14 (43%)
Cinema 2/68 (3%, 0·4–10·2 ) 0/28 1/25 (4%) 1/15 (7%)
Daily life 1/70 (1%, 0·0–7·7) 0/29 0/26 1/15 (7%)
TAT and F12
Flight 6/66 (9%, 3·4–18·7) 2/29 (7%) 2/23 (9%) 2/14 (14%)
Cinema 1/68 (2%, 0·0–7·9) 0/28 0/25 1/15 (7%)
Daily life 0/70 (0%, 0·0–5·1) 0/29 0/26 0/15
TAT, F12, and D-dimer
Flight 4/63 (6%, 1·8–15·5) 2/29 (7%) 1/23 (4%) 1/14 (7%)
Cinema 0/68 (0%, 0·0–5·3) 0/28 0/25 0/15
Daily life 0/70 (0%, 0·0–5·1) 0/29 0/26 0/15
Proportions of high responders tested by 2 without continuity correction or Fisher’s exact test when there were cells with ﬁve or less counts. Proportion of high responders after ﬂight
compared with daily life: TAT (p=0·002), TAT and F12 (p=0·01), TAT and F12 and D-dimer (p=0·048). Within response to ﬂight, proportion of high responders with 2 vs 0 risk factors:
TAT (p=0·04), TAT and F12 (p=0·58), TAT and F12 and D-Dimer (p=1·0).
Table 3: Proportion of high-responders per exposure, for whole group and by number of risk factors (oral contraceptive use, factor V Leiden mutation, or both)
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response in D-dimer concentrations in ﬁve individuals (5
of 63, 7·9%, 2·6–17·6; table 2, ﬁgure 3). The cinema
experiment triggered a high-response in D-dimer in one
other woman (1 of 68, 1·5%, 0·0–7·9) and the daily life
situation did so in two women (2 of 70, 2·9%, 0·4 to 9·9;
table 2, ﬁgure 3). 
Table 3 shows the number of high responders after each
exposure and for each combination of assays. We noted a
high response in both variables of thrombin generation
(F12 and TAT) in six volunteers after air travel, one
individual after the movie marathon, and in no-one after
the daily life situation (table 3). We also noted a high
response in both TAT and D-dimer in ﬁve volunteers after
the ﬂight, but not in the two control situations. A high-
response in all three variables (F12, TAT, and D-dimer)
was seen in four volunteers after the ﬂight, but not in
anyone after the two control situations (table 3). Table 3
also shows the proportions of high responders with no,
one, or two risk factors: the proportion of high responders
was consistently highest for the volunteers with two risk
factors. 
Discussion
Our ﬁndings indicate that ﬂight-associated factors—eg,
hypobaric hypoxia—lead to increased thrombin
generation after air travel, especially in individuals with
the factor V Leiden mutation who also took oral
contraceptives.
Results of other studies9–14 into the effects of hypobaric
hypoxia are conﬂicting, possibly because of the small
numbers involved or because of lack of control for the
effects of immobilisation and circadian rhythm. When
blood samples taken before and after a ﬂight are simply
compared, the differences noted can be the result of
various indistinguishable factors—eg, circadian rhythm,
immobilisation, or conditions present during the ﬂight,
like hypoxic hypobaria. To disentangle these factors, we
compared ﬁndings from blood samples taken at the same
time of day and from the same volunteers and looked at
three situations—immobilisation and hypoxic hypobaria
(ﬂight), normobaric immobilisation (cinema), and
normobaric non-immobilisation (daily life). We noted a
higher response in TAT values and in the combination of
an increase in TAT, F12, and D-dimer values after a
ﬂight than after a movie marathon or a period of normal
daily activity. 
Another explanation for the discrepancies between
studies might be that only some individuals are
susceptible to coagulation activation. Most studies do not
enrol individuals with risk factors for thrombosis, and,
when they do, results are presented at a group level,
diluting individual effects. Our ﬁndings concur with those
of previous studies3 (MEGA-study, unpublished data)
which show a synergistic effect for the combination of air
travel with either the factor V Leiden mutation or oral
contraceptive use. We are unaware of any study that has
looked at the risk of thrombosis in those ﬂying who have
both the factor V Leiden mutation and use oral
contraceptives. Yet about 5% of users of oral
contraceptives have the factor V Leiden mutation. As with
most risk factors for venous thrombosis a combination of
a genetic predisposition (factor V Leiden) and an
environmental factor (oral contraceptives, hypobaric
hypoxia) is probably the basis for venous thrombosis
associated with air travel. There must also be other factors
associated with clotting activation and thrombosis risk
after air travel, however, since individuals without these
characteristics can also develop travel-related venous
thrombosis. Indeed, we noted that the two women with
the highest TAT values neither took oral contraceptives
nor had the factor V Leiden mutation. 
Our study had various limitations. First, because of
practical constraints, we could not randomise the order of
the three exposure situations, nor could we blind the
volunteers to the exposures. Second, although experienced
laboratory technicians collected blood, conditions during
the study were more difﬁcult than those faced during a
routine blood draw in our clinic. However, conditions for
blood sampling during the ﬂight were similar to those
during the cinema exposure. The technicians had to
report any difﬁculties during blood sampling, which
occurred ﬁve times and only once during the ﬂight. Four
volunteers experienced a vasovagal collapse, but only
before and during the ﬂight, and not after; none of them
were high responders. We excluded all visibly haemolytic
samples. We investigated patterns of response related to
seating position or the designated technician, and noted
none. The seats in the cinema and in the airplane were
slightly different, but leg space was similar. So, although
there were practical difﬁculties, which we anticipated and
recorded, these are not likely to have affected our results.
Finally, some of the TAT values we noted in the high
responders were very high. We cannot exclude that some
of these values were artifacts due to preanalytic activation
of coagulation, though we did all we could to prevent such
confounding. Furthermore, that artifacts would arise only
after the ﬂight exposure, is unlikely. Nevertheless, we
repeated the analysis without the highest TAT values; we
noted no change to our overall conclusion. Although all
three variables showed some degree of clotting activation,
change was most apparent for TAT, both for the group as
a whole and in high responders. One explanation for this
ﬁnding could be a difference in sensitivity and speciﬁcity
of the assays, or a difference in clearance. The shorter half-
life of TAT (10 min vs 90 min for F12), could explain
why it is more sensitive to changes, since F12 will be
more diluted by what was already present. 
When air travel leads to coagulation activation, are there
alternative explanations to an effect of hypobaric hypoxia?
All factors present during ﬂights, but absent at other times
could theoretically explain the observed effects. Such
factors include anxiety and dehydration, neither of which
seems likely to have affected our participants: the ﬂight
was calm and uneventful, and the mood on the plane
Articles
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relaxed (individuals with a fear of ﬂying are unlikely to
have volunteered for our study), and dehydration, though
known to occur during ﬂying,16 has no known effect on
clotting. In any case, the volunteers were asked to keep
their ﬂuid intake constant during the three situations.
Temperature changes, poor air quality, vibration, noise,
acceleration, and electromagnetic radiation are also factors
noted in-ﬂight. However, to assume that any of these
conditions has an effect on the coagulation system would
be purely speculative.
Our participants, although some had common risk
factors for thrombosis, were young and healthy
individuals with no history of thrombosis. The effect of
ﬂying on the coagulation system of older individuals, or of
those with other risk factors for venous thrombosis or a
personal history of venous thrombosis, should also be
investigated. We conclude that the coagulation and
ﬁbrinolytic system are activated in some susceptible
individuals after an 8-h ﬂight, indicating an additional
mechanism to immobilisation for air travel related
thrombosis.
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